medical decision support medical decision support
Sign In

Targets of Block for Serum Phosphorus and the Calcium*Phosphorus Product in Patients with Chronic Renal Failure

Description

Hyperphosphatemia may occur in patients with chronic renal failure and is associated with development of secondary hyperparathyroidism. Control of calcium and phosphorus serum levels can help prevent some of the metabolic and cardiovascular complications experienced by patients with chronic renal failure.


 

calcium * phosphorus product =

= (serum calcium in mg/dL) * (serum phosphorus in mg/dL)

 

An elevated calcium-phosphorus product is associated with:

(1) visceral and vascular dystrophic calcification

(2) increased cardiovascular mortality in dialysis patients

 

Target

Desired Level

serum phosphorus

3.0 to 5.0 mg/dL

calcium * phosphorus product

< 55 (mg)^2 / (dL)^2

 


To read more or access our algorithms and calculators, please log in or register.

Specialty